Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.25+0.13 (+0.92%)
At close: 04:00PM EDT
14.18 -0.07 (-0.49%)
After hours: 04:07PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • a
    aaron
    Anyone get their dividend yet?
  • j
    jeffrey
    sweet, graham, sell your shares because it is going to be lower
  • P
    Peter
    No information about dividend payment history
    under historical information ...?
  • g
    graham
    Can anyone clarify the apparent delay in the Euro Regulators approving Takedas Dengu Vaccine. The phase3 trial data looks extremely good and reassuring. There is a definite need for this vaccine.
    Euro Regulators have been sitting on submission for more than a year???
  • j
    jeffrey
    profit drops a lot
  • t
    tomoki
    not yet …
  • b
    blackoutbuzz
    TAK ADR amazing shrinking dividend due to falling local currency. Annual payout is fixed at 180JPY/ordinary share. ADR:share ratio is 2;1, so 90JPY per ADR annually.

    USD/JPY=100 -> .90USD
    USD/JPY=125 -> 0.72USD
    USD/JPY=135 ->0.67USD
    USD/JPY=150 ->0.50USD

    Of course, since TAK derives ~70% of their revenue outside Japan (mainly US and Europe), weak FX will be a tailwind for earnings reported in Yen. Then there's the debt. See pp F44-46 of the annual 20-F for debt breakdown. Lots of USD and EUR denominated debt. ~10% of the total is denominated in JPY, but that can't be paid down until late 2024 at the earliest. The company has entered currency and interest rate swaps on large parts of their USD debt. Not sure how all these different ducks line up for TAK in the event of a Yen meltdown.

    @@@On June 6, 2019, Takeda issued hybrid subordinated bonds (the “Hybrid Bonds”) with an aggregate principal amount of 500 billion JPY. The proceeds from the Hybrid Bonds were used to repay the existing syndicated loans comprised of a senior short-term loan facility that was utilized to finance the acquisition of Shire. The Hybrid Bonds will mature on June 6, 2079. Under the terms and conditions of the Hybrid Bonds, Takeda may make an early repayment of all of the principal of the Hybrid Bonds on each interest payment date beginning October 6, 2024.

    @@@In 2017, Takeda entered into USD to JPY cross currency interest rate swap agreements to fix the interest rate for 925 million USD of the floating rate USD Syndicated Loans 2017. In respect of the remaining 575 million USD of the floating rate USD Syndicated Loans 2017, Takeda entered into an interest rate swap agreement to fix the applicable interest rate and also entered into a USD to JPY cross currency swap for 200 million USD of the fixed rate USD Unsecured Senior Notes issued in 2017. Furthermore, in 2020, Takeda entered into USD to JPY cross currency swaps on 1,750 million USD of the fixed rate 2018 USD Unsecured Senior Notes and 4,000 million USD of the fixed rate 2020 USD Unsecured Senior Notes.

    https://www.takeda.com/49f189/siteassets/system/investors/report/sec-filings/20-f_2021_06_29_en.pdf
  • g
    graham
    Note that today Takeda shares hit a 12 month low.
    This is despite the Yen hitting another LOW against the USD and approval of the new Covid vaccine.
    Takeda must be regretting the Shire takeover (a very bad deal) and their poor pipeline that will not deliver. A near 5% dividend does not compensate for the negatives.
  • G
    Great White Shaak
    $NVAX conversation
    It’s happening, Takeda is launching safer $nvax in Japan. It’s the end of $TAK assistance to $MRNA for Spikevax in 🇯🇵.

    Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna. I predicted this day will come (yesterday), more countries will follow and abandon the Mrna vaccines as they increase NVAX2373. Sorry GR8, your fired
    Bullish
  • g
    graham
    The notion that a weak yen will boost Takeda's exports is mistaken. The yen VALUE will benefit however real performance should show increasing volume. AZ has "suffered" from a WEAK POUND, however this has not affected them!!
    The Yen is at its historical low v the USD. DESPITE THIS the shares are underperformed.
    Exchange rates should be ignored and Takeda must be judged on fundamentals.
    The fundamentals are negative.
  • g
    graham
    Yen hits new low today and Takeda follows suit.
    Takeda is not a share that conforms to conventional wisdom.
    Takeda will hit new lows in coming months.
    Cut losses and sell.
  • g
    graham
    Takeda has a very speculative and HIGH RISK pipeline. Their recent manufacturing woes and approval delays point to a poorly managed Company.
    Takeda should follow the AZ model with carefully targeted single product acquisitions. I would avoid this share.
  • b
    blackoutbuzz
    Good update here. Profits will benefit from Yen weakness, and TAK continues to pursue the large revenue proposition in narcolepsy with their 'backup' drug in Phase 2.

    @@@Although Takeda reported a 10% decline in operating profit to 461 billion yen for the fiscal year that ended in March, analysts project, on average, that profit will almost double to a record 920 billion yen for the current fiscal period. That’s well above the company’s own forecast for 520 billion yen. On a core basis, which Takeda defines as excluding taxes, amortization and other charges, operating profit will be closer to 1.1 trillion yen. Takeda completed a 100 billion yen share buyback in April, and has kept dividends steady. Shareholders should expect this policy to continue, according to Constantine Saroukos, the drugmaker’s chief financial officer. “We’re very much focused on returning cash to our shareholders,” Saroukos, 51, said in the interview. This “could be in terms of dividend increases in the future, but also share buybacks,” and “with our free cash flow improving, gives us a lot more levers to pull to continue to drive shareholder returns,” he said. Takeda is assuming an exchange rate of 119 yen to the dollar for the current fiscal year, although this week the yen is trading at around 136 yen, near multidecade lows. If dollar-yen stays at around 130, “we’ll have single-digit, high single-digit upside on our revenue guidance and our earnings per share,” Saroukous said.

    @@@Both the CEO and CFO emphasized that the main beneficiary of the improved cash position will remain the development of new drugs and therapies. Takeda is “very committed” to the development of a drug to treat narcolepsy and is working hard to make up for an 18-month delay with a backup after terminating its leading project in October, Weber said. A backup compound called TAK-861 shows efficacy with “a much lower dose” than TAK-994 it scrapped after it caused problematic liver-damage side effects, Weber said. The new drug in development appears to be a better candidate, with mid-stage of clinical trials scheduled for later this year, although Weber declined to comment when the trial will be completed. “TAK-861’s market potential is equivalent of TAK-994,” said Weber. “We believe that it’s different enough to hope that it will not have the same safety issue while having the same level of efficacy, because the efficacy is mind blowing.”

    https://www.bnnbloomberg.ca/takeda-is-now-in-a-good-phase-for-growth-ceo-weber-says-1.1785782
    (Bloomberg) -- Takeda Pharmaceutical Co.’s shares might be trading at about half of their level before the $62 billion acquisition of Shire in 2018, but the drug pipeline and cash management are helping to change the market’s perception of the compan
    (Bloomberg) -- Takeda Pharmaceutical Co.’s shares might be trading at about half of their level before the $62 billion acquisition of Shire in 2018, but the drug pipeline and cash management are helping to change the market’s perception of the compan
    www.bnnbloomberg.ca
  • g
    graham
    Takeda's low p/e is a reflection of a pipeline that is high in quantity and low in quality.
    This, with poor management and high debt equals low p/e. Ha, of course, become even lower recently. Will need more than a weak yen and another Covid vaccine to.turn this around. A SELL!
  • J
    Jim
    tak is in dire need of new management.
  • T
    Tad
    $ARWR conversation
    from bikerieder on twitter:

    when pressed by madhu Kumar on talks with the fda concerning streamlining the aat trial, here was ca's response: Ca on aat study: “so Javier is probably dying to answer that question…but I can’t let him…here’s the deal. We were so excited about those data for a lot of reasons. I believe that it suggested this drug is doing what we wanted to do. In fact, doing a bit faster than we expected. And so we are going with those data and probably some additional data to the fda to talk about changing endpoints and changing size and maybe changing the duration of the study. Until we have those discussions, it’s probably not appropriate for us to speculate on the specifics of what those changes could be. I don’t want to get out in front of this conversation. We’ve had a very good collaborative relationship with the fda as it relates to this program, we expect this to continue to be collaborative, and I just don’t want to jeopardize that. I want to have the discussion, an open discussion with them and then come back to you and tell you what we have decided together.”

    then Mariano: "BIG STEP, $ARWR ARO-AAT showing polymer reduction both in liver cells and in serum. $TAK must have been convinced Arrowhead Pharma’s drug for A1AD will be a winner! Equates to same scenario as with $JNJ J&J purchase of ARO-HBV asset, too."

    color on the ongoing dialogue could come sooner than we think....just another short-term catalyst for arwr longs.
  • S
    Stuart
    Cathie bought 1.6 MILLION shares today
  • P
    PMA
    TAK announced almost $1 bn stock buyback in the next months.
    +12.8% growth y-o-y Revenue. Confirmed Full Year Management Guidance.
  • T
    The Great Correction
    Hey friends...

    Just arrived. Saw ARK's big purchase today and ended up here. I'm learning this isn't Cathy's first purchase.

    Does anyone know how many shares ARK is up to???

    Very strange ARK seems to be agressively accumulating but IV in options is super low.

    40% on the Jan 2022 $20s ????

    Any opinions???

    TIA
  • b
    blackoutbuzz
    Replagal contributed $471M in revenue to TAK in FY19. Sales of the drug grew 10%. It's a small fraction of the $30.2B in total revenues at the company. It is one of 14 key global brands for the firm, but hardly the end of the world if it sees some new competition.

    @@@Protalix BioTherapeutics, Inc. PLX and its partner Chiesi Global Rare Diseases, a unit of Chiesi, announced that they have submitted a biologics license application ("BLA") to the FDA for pegunigalsidase alfa (PRX-102). The BLA seeks approval for their lead candidate under accelerated approval pathway as a treatment for Fabry disease, a rare inherited genetic lysosomal disorder...The BLA includes data from a completed phase I/II study on pegunigalsidase alfa, including the related extension study, as well as interim data from the Phase III BRIDGE switch-over study and safety data from ongoing clinical studies of the candidate.The BRIDGE study is evaluating pegunigalsidase alfa in patients with Fabry disease who received treatment with Takeda’s TAK Fabry disease medicine, Replagal (agalsidase alfa) for at least two years and were on a stable dose for at least six months. The company announced positive top-line data from the study earlier this month. Data showed substantial improvement in renal function in patients treated with the candidate compared to patients receiving Replagal.

    https://finance.yahoo.com/news/protalix-submits-bla-fabry-disease-134301866.html
Advertisement
Advertisement